Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation

Transplantation

Volumn 62, Issue 6, 1996, Pages 759-763

  Kovarik, John M ^a   Mueller, Edgar A ^a   Richard, Francoise ^a   Niese, Detlef ^a   Halloran, F F ^b   Jeffery, J ^c   Paul, L C ^d   Keown, Paul A ^e  

^a Sandoz Pharma Ltd   (Switzerland)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; EMULSION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029742444     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609270-00010     Document Type: Article

References (10)

1. Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kutz K. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients: a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57: 1178.
2. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658.
3. Taesch S, Niese D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Transplant Int 1994; 7(suppl 1): S263.
4. Wahlberg J, Wilczek HE, Fauchald P, et al. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant patients over a one-year study period. Transplantation 1995; 60: 648.
5. Awni WM, Kasiske BL, Heim-Duthoy K, Roa KV. Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism. Clin Pharmacol Ther 1989; 45: 41.
6. 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood. Clin Chem 1988; 34: 257.
7. Schuirmann DJ. A comparison of the two one-sided procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657.
8. Grevel J, Post BK, Kahan BD. Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients. Clin Pharmacol Ther 1993; 53: 651.
9. Kahan BD, Kramer WG, Wideman C, Flechner SM, Lorver MI, Van Buren CT. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986; 41: 459.
10. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose-linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11: 301.